SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes

The goal of this clinical trial

The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:

• Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
• Does it cause more or fewer cardiovascular toxicity?
• What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.

Participants will:

• Be adults diagnosed with advanced lung cancer and type 2 diabetes.
• Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
• Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies

Inclusion Criteria:

• Lung cancer patients receiving standard anti-tumor treatment; type 2 diabetes; patients with a score of 0-2 assessed by Eastern Cooperative Oncology Group's performance status; the patients agreed to participate in this study.

Exclusion Criteria:

• Severe abnormalities in liver, kidney or heart functions; expected lifespan less than 3 months.